ArticleCell death & disease2020
Correction: Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3.
Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-Analysis.Cancer medicine · 2026Pooled it
- Vitamin D status in patients with oral leukoplakia and oral squamous cell carcinoma: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
- 1,25D3 reprograms mitochondrial quality control via sirtuin and sensitizes glioblastoma to chemotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The role of vitamin D deficiency in the development and severity of oral lichen planus: a case-control study.Clinical oral investigations · 2025Article
- Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy.American journal of cancer research · 2024Article
- Anticancer Activity and Molecular Targets ofBiomedicines · 2023Article
Corrections and comments
- Erratum for
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A correction to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.